Kailera Therapeutics, Inc. (KLRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kailera Therapeutics, Inc. (KLRA) closed at USD 10.74 on 2026-10-14, a change of -58.7 % over the past year, with a market capitalization of USD 1.52B.

Kailera Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kailera Therapeutics, Inc. key figures

Previous close

USD 10.74 (2026-10-14)

1-year change

-58.7 %

Market cap

USD 1.52B

Enterprise value

USD 611.6M

P/E ratio (trailing)

-2.39

P/E ratio (forward)

-2.73

EPS (trailing)

-4.91

EPS (forward)

-4.30

PEG ratio

n/a

Price to book

1.36

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.26

Employees

145

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kailera Therapeutics, Inc. and compare it with other stocks.